We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+0.75%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.44B
AUM Growth
-$102M
Cap. Flow
-$54M
Cap. Flow %
-2.21%
Top 10 Hldgs %
38.65%
Holding
187
New
10
Increased
35
Reduced
38
Closed
19

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$45.2M
2
HUM icon
Humana
HUM
+$23.9M
3
LLY icon
Eli Lilly
LLY
+$20.3M
4
ILMN icon
Illumina
ILMN
+$20.1M
5
ABT icon
Abbott
ABT
+$17.5M

Top Sells

Rank Stock Value
1
MCK icon
McKesson
MCK
+$44.1M
2
UNH icon
UnitedHealth
UNH
+$23.9M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$23.1M
4
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$21.7M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$21.3M

Sector Composition

Rank Sector Weight
1 Healthcare 96.9%
2 Real Estate 1.86%
3 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZBH icon
26
Zimmer Biomet
ZBH
$18.2B
$27.1M 1.11%
258,868
+116,824
+82% +$12.8M
ARGX icon
27
argenx
ARGX
$53.4B
$27.1M 1.11%
76,635
+38,179
+99% +$14.1M
MDT icon
28
Medtronic
MDT
$109B
$26.3M 1.08%
326,172
– –
RLYB icon
29
Rallybio
RLYB
$84.5M
$25.2M 1.03%
217,616
-23,774
-10% -$2.12M
UTHR icon
30
United Therapeutics
UTHR
$25.8B
$24.6M 1.01%
117,377
+45,171
+63% +$10.1M
JAZZ icon
31
Jazz Pharmaceuticals
JAZZ
$15.9B
$24.4M 1%
182,782
+14,883
+9% +$2.26M
HCA icon
32
HCA Healthcare
HCA
$87.2B
$22.8M 0.94%
124,303
– –
ZTS icon
33
Zoetis
ZTS
$32.4B
$20.3M 0.83%
136,914
-9,800
-7% -$1.64M
DXCM icon
34
DexCom
DXCM
$32.2B
$19.8M 0.81%
245,712
+115,828
+89% +$9.81M
ISRG icon
35
Intuitive Surgical
ISRG
$127B
$19.6M 0.8%
104,403
-1,773
-2% -$381K
GH icon
36
Guardant Health
GH
$21.5B
$18.6M 0.76%
346,084
-5,400
-2% -$277K
SRPT icon
37
Sarepta Therapeutics
SRPT
$1.57B
$18.3M 0.75%
165,959
-46,206
-22% -$4.66M
APLS
38
DELISTED
Apellis Pharmaceuticals
APLS
$18.2M 0.74%
266,076
-46,116
-15% -$2.73M
NBIX icon
39
Neurocrine Biosciences
NBIX
$16.8B
$17.9M 0.73%
168,108
– –
IDXX icon
40
Idexx Laboratories
IDXX
$44.1B
$17.7M 0.72%
54,207
+1,297
+2% +$476K
LNTH icon
41
Lantheus
LNTH
$6.49B
$16.1M 0.66%
229,179
+102,087
+80% +$7.73M
CRL icon
42
Charles River Laboratories
CRL
$11.2B
$14.3M 0.59%
72,675
+24,781
+52% +$5.35M
EW icon
43
Edwards Lifesciences
EW
$49.6B
$14.2M 0.58%
171,388
– –
RMD icon
44
ResMed
RMD
$30.6B
$13.3M 0.54%
60,699
-10,300
-15% -$2.34M
NVO
45
Novo Nordisk
NVO
$208B
$13M 0.53%
261,046
– –
BNTX icon
46
BioNTech
BNTX
$22.9B
$12.8M 0.52%
95,042
– –
BMRN icon
47
BioMarin Pharmaceuticals
BMRN
$11.6B
$12.8M 0.52%
150,947
+22,943
+18% +$2.04M
IQV icon
48
IQVIA
IQV
$38.7B
$12.3M 0.5%
67,817
-16,486
-20% -$3.61M
CVS icon
49
CVS Health
CVS
$133B
$11.8M 0.48%
123,803
– –
XBI icon
50
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$11.7M 0.48%
147,677
-61,477
-29% -$5.18M
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Tekla Capital Management held 187 positions worth $2.44B, down 4% from $2.54B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q3 2022 filing shows 10 new, 35 increased, 38 reduced and 19 closed positions. Its largest new stake was Veradigm Inc. Common Stock: 428,580 shares worth $6.53M. The largest sale was McKesson, an estimated $44.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q3 2022 buy was Veradigm Inc. Common Stock: 428,580 shares worth $6.53M.
  • Tekla Capital Management added most to Johnson & Johnson in Q3 2022, an estimated $45.2M increase.
  • Tekla Capital Management's biggest Q3 2022 reduction was McKesson, cutting an estimated $44.1M.
  • Tekla Capital Management fully exited Syneos Health, Inc. Class A Common Stock in Q3 2022, selling an estimated $21.7M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.44B portfolio in Q3 2022.
  • Tekla Capital Management opened 10 new positions and closed 19 in Q3 2022.
  • Tekla Capital Management's portfolio value fell 4% quarter-over-quarter to $2.44B.

Based on Tekla Capital Management's 13F filing for Q3 2022, filed 1 Nov 2022.